Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Marker Chromosomes Are a New Cytogenetic Adverse Risk Factor in AML after Allo-HCT

Kyoko Fuse, MD, Tomoyuki Tanaka, MD PhD, Shun Uemura, MD, Tatsuya Suwabe, MD, Takayuki Katagiri, MD, Takashi Ushiki, MD PhD, Yasuhiko Shibasaki, MD, Naoko Sato, MD PhD, Toshio Yano, MD PhD, Takashi Kuroha, MD PhD, Shigeo Hashimoto, MD PhD, Tastuo Furukawa, MD PhD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2018) 132 (Supplement 1): 5260.

https://doi.org/10.1182/blood-2018-99-113251

Published: 2018

Journal Articles

Patient-Based Prediction Algorithm of Relapse after Allo-HSCT for Acute Leukemia Using Machine Learning Approach

Kyoko Fuse, MD, Shun Uemura, MD, Tatsuya Suwabe, MD, Takayuki Katagiri, MD, Tomoyuki Tanaka, MD, Takashi Ushiki, MD PhD, Yasuhiko Shibasaki, MD PhD, Naoko Sato, MD PhD, Toshio Yano, MD PhD, Takashi Kuroha, MD PhD, Shigeo Hashimoto, MD PhD, Tastuo Furukawa, MD PhD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2017) 130 (Supplement 1): 2044.

https://doi.org/10.1182/blood.V130.Suppl_1.2044.2044

Published: 2017

Journal Articles

The Predictive Factors of Favorable Prognosis after Allo-HSCT for Refractory Acute Leukemia

Kyoko Fuse, MD, Takayuki Katagiri, MD, Yasuhiko Shibasaki, MD PhD, Tomoyuki Tanaka, MD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD, Tatsuo Furukawa, MD PhD, Naoko Sato, MD PhD, Toshio Yano, MD PhD, Takashi Kuroha, MD PhD, Shigeo Hashimoto, MD PhD, Takashi Ushiki, MD PhD

Blood (2016) 128 (22): 2297.

https://doi.org/10.1182/blood.V128.22.2297.2297

Published: 2016

Journal Articles

A Unique Immunotherapeutic Atrategy by Using a Leukemic Plasmacytoid Dendritic Cell Line (PMDC05) as Potent Antigen Presenting Cells.

Takeshi Nakamura, Miwako Narita, MD, Akie Yamahira, Norihiro Watanabe, Nozomi Tochiki, Anri Saitoh, Masami Kaji, Tomoyo Taniguchi, Shigeo Hashimoto, MD, Tatsuo Furukawa, MD, Ken Toba, MD, Ichiro Fuse, MD, Yoshifusa Aizawa, MD, Masuhiro Takahashi, MD

Blood (2009) 114 (22): 5117.

https://doi.org/10.1182/blood.V114.22.5117.5117

Published: 2009

Journal Articles

Human Plasmacytoid Dendritic Cell like Leukemia Cell Line (PMDC05) Established from a Patient with CD4 + CD56 + Acute Leukemia.

Miwako Narita, MD, Nozomi Tochiki, Norihiro Watanabe, Anri Saitoh, Shigeo Hashimoto, MD, Junjiro Tsuchiyama, MD, Tatsuo Furukawa, MD, Sadao Aoki, MD, Ichiro Fuse, MD, Yoshifusa Aizawa, MD, Masuhiro Takahashi, MD

Blood (2006) 108 (11): 4456.

https://doi.org/10.1182/blood.V108.11.4456.4456

Published: 2006

Journal Articles

Anti-Tumor Cytotoxicity of Blood γδ T Cells Expanded from Leukemia Patients Against Autologous Leukemia Cells—Enhancement of the Anti-Tumor Cytotoxicity by Type I IFN.

Anri Saito, Miwako Narita, MD, Norihiro Watanabe, Ayumi Yokoyama, Asuka Sekiguchi, Nozomi Tochiki, Louie Alldawi, MD, Jun Takizawa, MD, Shigeo Hashimoto, MD, Tatsuo Furukawa, MD, Ken Toba, MD, Yoshifusa Aizawa, MD, Masuhiro Takahashi, MD

Blood (2005) 106 (11): 2385.

https://doi.org/10.1182/blood.V106.11.2385.2385

Published: 2005

Journal Articles

Human Plasmacytoid Dendritic Cell Line (PMDC05) Established from a Patient with CD4 + CD56 + Acute Leukemia.

Miwako Narita, MD, Nozomi Tochiki, Shigeo Hashimoto, MD, Asuka Sekiguchi, Norihiro Watanabe, Ayumi Yokoyama, Anri Saitoh, Junjiro Tsuchiyama, MD, Toshio Yano, MD, Masayoshi Masuko, MD, Ken Toba, MD, Tatsuo Furukawa, MD, Yoshifusa Aizawa, MD, Masuhiro Takahashi, MD

Blood (2005) 106 (11): 4330.

https://doi.org/10.1182/blood.V106.11.4330.4330

Published: 2005

Journal Articles

The Useful Individualized Assessment of Immunosuppressive Therapy with Cyclosporine A (CsA) after Allogeneic Stem Cell Transplantation by Simultaneous Analyses of Cytokine Production among CD4+ T Cells and Blood CsA Levels.

Nobuhiro Tsukada, MD, PhD, Tatsuo Furukawa, MD, PhD, Hiromi Ito, Noriko Izumi, MD, Akihito Momoi, MD, Kiyoshi Okazuka, MD, Keiichiro Honma, MD, Masayoshi Masuko, MD, PhD, Shigeo Hashimoto, MD, PhD, Sadao Aoki, MD, PhD, Yoshifusa Aizawa, MD, PhD

Blood (2004) 104 (11): 5076.

https://doi.org/10.1182/blood.V104.11.5076.5076

Published: 2004

NARROW

Marker Chromosomes Are a New Cytogenetic Adverse Risk Factor in AML after Allo-HCT

Patient-Based Prediction Algorithm of Relapse after Allo-HSCT for Acute Leukemia Using Machine Learning Approach

The Predictive Factors of Favorable Prognosis after Allo-HSCT for Refractory Acute Leukemia

A Unique Immunotherapeutic Atrategy by Using a Leukemic Plasmacytoid Dendritic Cell Line (PMDC05) as Potent Antigen Presenting Cells.

Human Plasmacytoid Dendritic Cell like Leukemia Cell Line (PMDC05) Established from a Patient with CD4 + CD56 + Acute Leukemia.

Anti-Tumor Cytotoxicity of Blood γδ T Cells Expanded from Leukemia Patients Against Autologous Leukemia Cells—Enhancement of the Anti-Tumor Cytotoxicity by Type I IFN.

Human Plasmacytoid Dendritic Cell Line (PMDC05) Established from a Patient with CD4 + CD56 + Acute Leukemia.

The Useful Individualized Assessment of Immunosuppressive Therapy with Cyclosporine A (CsA) after Allogeneic Stem Cell Transplantation by Simultaneous Analyses of Cytokine Production among CD4+ T Cells and Blood CsA Levels.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only